Sponsored by:

Molecular Imaging: Page 81

PET/CT classifies subtypes in progressive nuclear palsy
By Will Morton
Monday, November 29 | 3:00 p.m.-4:00 p.m. | SSNMMI04-4 | Room S405In this session on brain imaging, researchers from India will present a study that elucidates patterns of characteristic hypometabolism on F-18 FDG PET/CT in various subtypes of progressive nuclear palsy and their correlation with core clinical features.
November 22, 2021
Is PET radiotracer uptake in lymph nodes after COVID-19 vaccination associated with age?
By Will Morton
Monday, November 29 | 9:30 a.m.-10:30 a.m. | SSNMMI03-6 | Room S402Israeli researchers will offer findings in this presentation on PET/CT uptake in the deltoid muscle and axillary lymph nodes in patients who received COVID-19 mRNA-based vaccines. The group explored whether uptake is associated with patient age and immune status.
November 22, 2021
PET with F-18 fluoroestradiol tracer evaluated in women with breast cancer
By Will Morton
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-2 | Room N226In this talk, researchers will discuss results of the first prospective study evaluating the performance of F-18 fluoroestradiol PET/CT in women with invasive lobular carcinoma breast cancer.
November 22, 2021
2017 11 07 18 37 9362 Roadies Ribbon 400
Ultrafast low-dose PET/CT equivalent to conventional imaging for cancer
By Will Morton
Sunday, November 28 | 2:30 p.m.-3:30 p.m. | SSNMMI02-2 | Room N226In this session covering technical advances in molecular imaging, researchers will present findings of a prospective phase III trial comparing an ultrafast, low-dose, whole-body FDG-PET/CT approach with conventional imaging in patients with cancer.
November 22, 2021
PET tracers can verify patient response to HIFU treatment
By Will Morton
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-5 | Room N226In this molecular oncologic imaging presentation, researchers will report on the use of gallium-68-based radiotracers to assess response to high-intensity focused ultrasound (HIFU) therapy in prostate cancer patients.
November 22, 2021
Combining radiomics, AI with PET/MRI helps assess nodal status
By Amerigo Allegretto
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-3 | Room N226Here, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.
November 21, 2021
Monrol and MTTI ink Lu-177 supply deal
By AuntMinnie.com staff writers
EczacıbaŞı-Monrol Nuclear Products has signed an agreement to supply Molecular Targeting Technologies (MTTI) with no-carrier-added lutetium-177 (Lu-177).
November 18, 2021
2019 12 19 00 53 5252 Hands Shaking Deal 400
PSMA-PET predicts patient response to chemotherapy
By Will Morton
PET imaging with a radiotracer based on prostate-specific membrane antigen (PSMA) can help predict whether patients with metastatic prostate cancer will respond to chemotherapy, a significant finding in efforts to tailor therapy to individual patients, according to a study published November 12 in the Journal of Nuclear Medicine.
November 18, 2021
2021 11 18 19 23 1267 2021 11 19 Psma Pet 400
NorthStar to buy accelerator for actinium-225 production
By AuntMinnie.com staff writers
NorthStar Medical Radioisotopes has inked a deal with Ion Beam Applications (IBA) to purchase one of IBA's Rhodotron TT300 HE electron-beam accelerators for the commercial production of actinium-225 (Ac-225) at its new production facility in Beloit, WI.
November 17, 2021
2019 06 27 17 42 3952 Business Man Handshake 400
Emory's Meltzer tapped to lead USC medical school
By AuntMinnie.com staff writers
Dr. Carolyn Meltzer of Emory University has been named as dean of the Keck School of Medicine at the University of Southern California (USC).
November 16, 2021
2021 11 17 18 22 5360 Meltzer Carolyn 2021 400
MIM gets FDA nod for molecular radiotherapy software
By AuntMinnie.com staff writers
Medical imaging software developer MIM software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SurePlan MRT molecular radiotherapy software.
November 16, 2021
2020 07 09 20 52 8488 Mim Astro 2019 400
PET/MRI shows prowess for nodal staging in breast cancer
By Amerigo Allegretto
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-4 | Room TBAIn this presentation, researchers will compare nodal staging between CT, MRI, and FDG-PET/MRI in patients with newly diagnosed breast cancer.
November 15, 2021
Previous Page
Page 81 of 611
Next Page